VYGR: Lower collaboration revenue, reduced spend and cash runway into Q2 2028 define the quarter

Q3 collaboration revenue fell to $4.0M, while lower operating expenses helped narrow net loss to $24.7M YoY. Cash, equivalents and marketable securities of $132.1M, with expected partner reimbursements and interest, are projected to support operations into Q2 2028.

Original document: Voyager Therapeutics, Inc. [VYGR] SEC 10-Q Quarterly Report — Nov. 5 2026